Trade VBI Vaccines Inc. - VBIV CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.05 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.024124% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001901% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 0.52 |
| Open | 0.52 |
| 1-Year Change | -60% |
| Day's Range | 0.52 - 0.53 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Jul 29, 2024 | 0.53 | 0.00 | 0.00% | 0.53 | 0.53 | 0.52 |
| Jul 26, 2024 | 0.52 | 0.01 | 1.96% | 0.51 | 0.53 | 0.50 |
| Jul 25, 2024 | 0.52 | 0.01 | 1.96% | 0.51 | 0.52 | 0.48 |
| Jul 24, 2024 | 0.53 | -0.03 | -5.36% | 0.56 | 0.56 | 0.51 |
| Jul 23, 2024 | 0.56 | -0.01 | -1.75% | 0.57 | 0.58 | 0.54 |
| Jul 22, 2024 | 0.59 | 0.03 | 5.36% | 0.56 | 0.61 | 0.55 |
| Jul 19, 2024 | 0.57 | -0.07 | -10.94% | 0.64 | 0.65 | 0.57 |
| Jul 18, 2024 | 0.63 | -0.07 | -10.00% | 0.70 | 0.72 | 0.59 |
| Jul 17, 2024 | 0.70 | -0.02 | -2.78% | 0.72 | 0.72 | 0.69 |
| Jul 16, 2024 | 0.70 | -0.04 | -5.41% | 0.74 | 0.75 | 0.70 |
| Jul 15, 2024 | 0.73 | -0.03 | -3.95% | 0.76 | 0.76 | 0.73 |
| Jul 12, 2024 | 0.76 | 0.02 | 2.70% | 0.74 | 0.77 | 0.72 |
| Jul 11, 2024 | 0.74 | 0.01 | 1.37% | 0.73 | 0.75 | 0.70 |
| Jul 10, 2024 | 0.73 | 0.01 | 1.39% | 0.72 | 0.73 | 0.70 |
| Jul 9, 2024 | 0.72 | -0.01 | -1.37% | 0.73 | 0.73 | 0.70 |
| Jul 8, 2024 | 0.72 | 0.00 | 0.00% | 0.72 | 0.74 | 0.72 |
| Jul 5, 2024 | 0.70 | -0.01 | -1.41% | 0.71 | 0.71 | 0.68 |
| Jul 3, 2024 | 0.70 | -0.02 | -2.78% | 0.72 | 0.75 | 0.69 |
| Jul 2, 2024 | 0.69 | 0.04 | 6.15% | 0.65 | 0.75 | 0.65 |
| Jul 1, 2024 | 0.66 | 0.02 | 3.13% | 0.64 | 0.67 | 0.64 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
VBI Vaccines Inc. Company profile
VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for the treatment of chronic HBV infection. The company''s enveloped virus-like particle (eVLP) platform technology allows for the development of eVLP vaccines that mimic the presentation of viruses to elicit a human immune system. Its lead eVLP program candidates include VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study; and VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial. The company also develops coronavirus vaccine candidates, such as VBI-2902 and VBI-2901. In addition, it engages in the development of vaccine platforms and products for licensing to pharmaceutical companies and biotechnology companies. The company primarily serves physicians and pharmacists through direct sales. It has collaboration and license agreements with Brii Biosciences Limited; and GlaxoSmithKline Biologicals S.A. The company also has a collaboration with the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. VBI Vaccines Inc. has collaboration with Coalition For Epidemic Preparedness Innovations to advance vaccine candidates against Covid-19 variants. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is headquartered in Cambridge, Massachusetts.| Industry: | Biotechnology & Medical Research (NEC) |
160 Second Street
Cambridge
CAMBRIDGE
MASSACHUSETTS 02142
US
News
Gold price predictions for the next five years: Third party data round up
Explore the future of gold prices and whether the yellow metal will continue its upward trend in the coming years.
15:17, 18 November 2024
Shiba Inu coin price prediction 2030: could Shiba Inu coin reach $1? Third party price target
Can Shiba Inu reinvent itself to become a worthy long-term investment?
08:36, 15 November 2024
Trump trades charge as Bitcoin hits $US80,000
Bitcoin hits $80,000 amid expectations of fiscal stimulus, lower regulatory risks, and resilient US economy.
10:48, 13 November 2024
Australian jobs data expected to point to solid labour market conditions
Australian labour market and wage data to reveal job growth resilience, shaping RBA rate cut expectations and impacting AUD amidst global economic shifts.
10:16, 13 November 2024
FOMC cuts interest rates as expected and sticks to its line on future policy
The FOMC cut interest rates by 25 basis points at its November meeting, aligning with expectations. Wall Street hit record highs following the decision, with tech stocks leading the rally. Markets are pricing in a probable December cut amid resilient economic indicators.
13:33, 8 November 2024
FOMC and BOE preview: further rate cuts expected
Both the Federal Reserve and the Bank of England are expected to cut rates further when they meet later this week.
14:14, 5 November 2024
RBA meeting preview: No change to policy expected as inflation fight continues
The Reserve Bank of Australia is expected to keep its cash rate on hold at 4.35% when it announces its policy decision at 2.30PM on the 5th of November, 2024. Despite ongoing evidence of soft demand, upside risks to inflation are likely to remain the central bank’s primary concern.
13:35, 4 November 2024People also watch
Still looking for a broker you can trust?
Join the 660,000+ traders worldwide that chose to trade with Capital.com